Purchase this article with an account.
Shengyan Liu, Matthew Daniel Dozois, Deborah Li Ting Ng, Chuning Chang, Denise Hileeto, Lyndon William Jones, Frank Gu; Weekly dosing regimen of eye drop formulations delivered through mucoadhesive nanoparticles enhances treatment of experimental dry eye. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5036.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the long term efficacy of using once a week dosing of Cyclosporine A (CsA) loaded mucoadhesive nanoparticle eye drop formulation in treating dry eye syndrome (DES).
Experimental DES in mice was induced by applying scopolamine patches to their midtails and exposing them to desiccating environments. These mice were treated with various formulations including Restasis (thrice daily), nanoparticles without CsA (Blank NPs, once a week), CsA-loaded nanoparticles with a CsA dosage 1-2% that of Restasis (CsA-NP 1-2%, once a week) or CsA-NP 5% (once a week) for a month. Dry eye status was evaluated using tear production measurement, corneal fluorescein clearance, and histopathology analysis.
After 4 weeks of treatment period, the once a week administration of CsA-NP 5% and thrice daily administration of Restasis both showed elimination of inflammatory signs, but did not recovery the integrity of the ocular surface tissues. The once a week administration of CsA-NP 1-2% showed both the elimination of the inflammation and full recovery of the ocular surface.
Weekly dosing regimen of CsA loaded mucoadhesive nanoparticle eye drop platform demonstrated effective treatment of experimental dry eye in mice with up to 50 to 100 fold reduction in overall dosage compared to Restasis, which may significantly reduce side effects and improve patient compliance.
This PDF is available to Subscribers Only